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Identification of Alternative Transcripts Encoding the Essential
Murine Gammaherpesvirus Lytic Transactivator RTA
Brian S. Wakeman,a L. Steven Johnson,b Clinton R. Paden,a Kathleen S. Gray,a Herbert W. Virgin,b Samuel H. Specka
Emory Vaccine Center and Department of Microbiology & Immunology, Emory University School of Medicine, Atlanta, Georgia, USAa; Department of Pathology and
Immunology, Washington University School of Medicine, St. Louis, Missouri, USAb

The essential immediate early transcriptional activator RTA, encoded by gene 50, is conserved among all characterized gammaherpesviruses. Analyses of a recombinant murine gammaherpesvirus 68 (MHV68) lacking both of the known gene 50 promoters
(G50DblKo) revealed that this mutant retained the ability to replicate in the simian kidney epithelial cell line Vero but not in
permissive murine fibroblasts following low-multiplicity infection. However, G50DblKo replication in permissive fibroblasts
was partially rescued by high-multiplicity infection. In addition, replication of the G50DblKo virus was rescued by growth on
mouse embryonic fibroblasts (MEFs) isolated from IFN-␣/␤Rⴚ/ⴚ mice, while growth on Vero cells was suppressed by the addition of alpha interferon (IFN-␣). 5= rapid amplification of cDNA ends (RACE) analyses of RNAs prepared from G50DblKo and
wild-type MHV68-infected murine macrophages identified three novel gene 50 transcripts initiating from 2 transcription initiation sites located upstream of the currently defined proximal and distal gene 50 promoters. In transient promoter assays, neither
of the newly identified gene 50 promoters exhibited sensitivity to IFN-␣ treatment. Furthermore, in a single-step growth analysis
RTA levels were higher at early times postinfection with the G50DblKo mutant than with wild-type virus but ultimately fell below the levels of RTA expressed by wild-type virus at later times in infection. Infection of mice with the MHV68 G50DblKo virus
demonstrated that this mutant virus was able to establish latency in the spleen and peritoneal exudate cells (PECs) of C57BL/6
mice with about 1/10 the efficiency of wild-type virus or marker rescue virus. However, despite the ability to establish latency,
the G50DblKo virus mutant was severely impaired in its ability to reactivate from either latently infected splenocytes or PECs.
Consistent with the ability to rescue replication of the G50DblKo mutant by growth on type I interferon receptor null MEFs,
infection of IFN-␣/␤Rⴚ/ⴚ mice with the G50DblKo mutant virus demonstrated partial rescue of (i) acute virus replication in the
lungs, (ii) establishment of latency, and (iii) reactivation from latency. The identification of additional gene 50/RTA transcripts
highlights the complex mechanisms involved in controlling expression of RTA, likely reflecting time-dependent and/or cell-specific roles of different gene 50 promoters in controlling virus replication. Furthermore, the newly identified gene 50 transcripts
may also act as negative regulators that modulate RTA expression.
IMPORTANCE

The viral transcription factor RTA, encoded by open reading frame 50 (Orf50), is well conserved among all known gammaherpesviruses and is essential for both virus replication and reactivation from latently infected cells. Previous studies have shown
that regulation of gene 50 transcription is complex. The studies reported here describe the presence of additional alternatively
initiated, spliced transcripts that encode RTA. Understanding how expression of this essential viral gene product is regulated
may identify new strategies for interfering with infection in the setting of gammaherpesvirus-induced diseases.

H

erpesviruses are large double-stranded DNA viruses. The
hallmark of all herpesvirus infections is their ability to persist
latently for the lifetime of the host, which is marked by sporadic
virus reactivation, replication, and shedding. The herpesvirus
family is divided into three classes, the alpha-, beta-, and gammaherpesviruses. While both alpha- and betaherpesviruses generally
exhibit broad tropism and the ability to infect a range of cell types,
gammaherpesviruses are unique in that they are mainly lymphotropic, infecting and establishing latency in T or B lymphocytes.
Gammaherpesviruses are also unique in that they are associated
with a variety of lymphomas. Kaposi’s sarcoma-associated virus
(KSHV) is associated with tumor development in its namesake
Kaposi’s sarcoma, as well as multicentric Castleman’s disease and
primary effusion lymphoma. Epstein-Barr virus (EBV) is tightly
associated with the development of several human malignancies,
including nasopharyngeal carcinoma, Hodgkin’s lymphoma,
Burkitt’s lymphoma, and posttransplant lymphoproliferative disease (1). Though both KSHV- and EBV-associated malignancies
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are rare, their prevalence is elevated in people who are immunocompromised via either immunosuppressive therapies or HIV infection (2–4).
While in vitro cell culture systems exist to study the two human
gammaherpesviruses EBV and KSHV, these viruses have a narrow
host tropism which severely limits in vivo studies. This has generated a need for robust small-animal models to further investigate
primary viral infection, establishment of latency, and reactivation
in the context of natural infection. Murine gammaherpesvirus 68
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ABSTRACT

Alternative MHV68 Gene 50 Transcripts

(MHV68) has emerged as the leading animal model for characterizing gammaherpesvirus pathogenesis in vivo. MHV68 is a natural
pathogen of wild murid rodents and readily infects laboratory
strains of mice (5). Complete sequencing of the MHV68 genome
revealed extensive homology to those of both EBV and KSHV (6).
MHV68 infects multiple organs, establishes latency in the spleen
and lymph nodes, is primarily lymphotropic, and is associated
with development of lymphoproliferative disease and lymphomas
(7–9).
An area of the MHV68 genome that is well conserved in both
sequence homology and function is the gene 50 region, which
encodes the essential immediate early viral transcriptional activator RTA (also known as R or BRLF1). Notably, the MHV68,
KSHV, and EBV gene 50 transcripts exhibit similar splicing patterns, promoters, and genome locations (Fig. 1). Furthermore,
ectopic expression of RTA in cells latently infected with MHV68,
herpesvirus saimiri (HVS), KSHV, and EBV is capable of driving
virus reactivation (10, 11), mediated through RTA activation of
viral lytic cycle-associated gene promoters (12, 13–15). RTA feeds
into many different lytic and latent gene pathways, acting as both
a positive and negative regulator of gene transcription. The many
important functions exhibited by RTA make it one of the most
tightly regulated genes in gammaherpesviruses where control is
established through the use of alternative splicing, epigenetic
modifications, feedback loops, and multiple promoters.
Recently we identified a new RTA promoter, which we named
the distal gene 50 promoter (16). Notably, we previously showed
that this promoter is also present in KSHV and EBV (Fig. 1). The
transcript initiated from the distal promoter encodes a 181-bp
exon (E0) at coordinates bp 65909 to 66089 in the MHV68 genome, which splices to the E1 exon located at coordinates bp
66509 to 66796 and then splices to exon 2 at coordinates bp 67662
to 69462. Notably, we have shown that a proximal gene 50 mutant
virus is able to replicate, establish latency in both splenocytes and
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MATERIALS AND METHODS
Generation of G50DblKo and G50DblKo.MR viruses. The MHV68.
G50DblKo virus was generated using the galK-mediated Red recombineering method as described previously (17, 18). Briefly, we introduced
the MHV68 bacterial artificial chromosome (BAC) into the galK
bacterial strain SW102, where the galK was inserted into the Orf50 locus.
To generate the Orf50-galK swap, we amplified the galK gene from the
plasmid pGalK using the primers GalK-G50-F (5=-CTTAAAGGAGGAG
CTGTTGGCAGTGCTTGCTGAAAATACCTCATCAAACTCCTGTTG
ACAATTAATCATCGGCA-3=) and GalK-G50-R (5=-CCTCAGCCTTT
GAAGGGACATTTCATGACTCATGTAGGAGGAGCTACCAGTCAGC
ACTGTC CTGCTCCTT-3=); this PCR product generated from pGalK
includes 50 bp of homologous sequence upstream and downstream from
the Orf50 locus. The PCR product was then introduced into the SW102
cells through electroporation, and those cells expressing recombinants
were selected through the use of minimal medium with galactose. The
ORF50/GalK recombinant BAC mutants (MHV68.⌬50galK) were confirmed through analyses using multiple restriction endonucleases.
To generate the G50DblKo virus, two separate PCRs with 25-l
reaction mixtures were performed on MHV68 WT BAC with 30 cycles
using Phusion polymerase (New England BioLabs) and the following cycling conditions: 94°C for 30 s, 58°C for 30 s, and 72°C for 1
min. The primers used for reaction one amplification were forward
primer Orf50F65040_65089 (5=-CTTAAAGGAGGAGCTGTTGGCA
GTGCTTGCTGAAAATACCTCATCAAACT-3=) with reverse primer
Orf50DpKo100RHindIII (5=-AATGGACTCCAGCTGAAGCTTAGT
CATAGAACATACCATGA-3=), and the primers used for reaction two
amplification were reverse primer Orf50R66641_66690 (5=-CCTCAG
CCTTTGAAGGGACATTTCATGACTCATGTAGGAGGAGCTACCA
G-3=) with forward primer Orf50DpKo100FHindIII (5=-GTATGTTC
TATGACTAAGCTTCAGCTGGAGTCCATTATTCT-3=), generating
overlapping PCR products to be used in round two amplification (of
note, each internal primer contained a HindIII restriction enzyme site
to be used for diagnostic purposes). Two microliters of each round one
amplification product was then used as the template for a round two
reaction using the external forward primer from reaction one
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FIG 1 Genomic alignment of Orf50/BRLF1/Rta regions from MHV68, EBV,
KSHV, and HVS gammaherpesviruses, illustrating the conserved organization
of gene 50 transcription. A schematic diagram of the Orf50 region with exon 2,
exon 1, and recently discovered exon 0 is shown. The antisense coding regions
Orf48/BRRF2 and Orf49/BRRF1 are shown to demonstrate the conserved organizational context. The boxes around exon 1 and exon 0 shown their relative
positions within the genome. The nucleotide positions of exon 0 (E0), exon 1
(E1), and exon 2 (E2) are given.

peritoneal exudate cells (PECs), and reactivate from PECs, suggesting that the distal promoter is functional (16). However, the
proximal-promoter mutant is defective in reactivation from
splenocytes (16).
Here we demonstrate that the expression of RTA can be driven
from multiple previously unknown promoters upstream of the
distal promoter. These promoters encode three new exons, two of
which represent extensions of exon 0 and the other a completely
unique exon. To further characterize these promoters, we generated an MHV68 mutant lacking both the proximal and distal gene
50 promoters (G50DblKo). We show the G50DblKo virus retains
the ability to replicate to levels similar to those for the wild-type
(WT) virus, but only in the absence of a type I interferon (IFN)
response. Furthermore, we show that the G50DblKo virus is extremely sensitive to type I interferons both in vitro and in vivo. We
also show that despite the replication defect observed in the presence of a type I interferon response, the G50DblKo virus established a latent infection in both splenocytes and PECs, although it
was unable to reactivate from either splenocytes or PECs. Importantly, the replication and latency defects exhibited by the
G50DblKo mutant were largely rescued by infection of mice lacking a type I interferon response. Finally, despite the sensitivity of
the G50DblKo mutant virus to type I IFNs, we show that the newly
identified promoters themselves are not directly sensitive to
IFN-␣, indicating that type I IFNs likely act downstream of RTA
transcription.

Wakeman et al.
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were added to the cellular monolayer, and plates were rocked every 15 min
at 37°C for 1 h. After 1 h, fresh cMEM at a volume of 2 ml was added back
to each well. The contents of the wells were collected at the indicated time
points and frozen at ⫺80°C until plaque assays were performed to determine titers. Growth curves with the addition of mouse recombinant
IFN-␣ (Miltenyi Biotec) were performed in a similar manner, but IFN-␣
was added to the plated cells at a concentration of 10,000 IU/ml 1 h before
infection. IFN-␣ was subsequently added at a concentration of 5,000
IU/ml every 24 h for the duration of the infection. Plaque assays were
performed by plating Vero-Cre cells in six-well plates at a concentration of
1.75 ⫻ 105 cells per well 24 h prior to infection. Viral stocks or growth
curve stocks at the indicated time points were freeze-thawed 3 times, and
a 10-fold serial dilution was generated, 200 l of each dilution was added
to the Vero-Cre monolayer, and plates were rocked every 15 min at 37°C
for 1 h. After 1 h, cells were overlaid with 2% fetal bovine serum (FBS)
complete medium containing 20 g/liter methylcellulose (Sigma). Plaques
were visualized at 14 days postinoculation by staining with neutral red
(Sigma) at a concentration of 6% overnight.
RACE analysis. One-hundred-millimeter plates were seeded with
Raw 264.7, Vero-Cre, or IFN-␣/␤R⫺/⫺ MEF cells in cMEM and 24 h later
were infected with WT-YFP or G50DblKo virus at an MOI of 5. Total
RNA was isolated from these cells at 24 or 48 h postinfection using TRIzol
reagent (Invitrogen). Five micrograms of RNA was DNase I treated (Invitrogen) and subjected to 5= rapid amplification of cDNA ends (RACE)
performed using the GeneRacer system (Invitrogen). RACE-ready cDNA
was generated using Superscript III (Invitrogen) reverse transcription using random primers as per the manufacturer’s instructions. RACE-ready
cDNA was used to look for additional 5= transcripts through the use of
nested PCR utilizing Phusion high-fidelity Taq (NEB) and Platinum Taq
(Invitrogen). Nested PCR was performed using the 5= universal forward
primer (round 1), the 5= universal forward primer (round 2), and various
reverse primers located in the Orf50 region: E2R1 (5=-ATTTCGAACAG
ACTGCAGGCCAGAGGTTGA-3=), E2R2 (5=-CGAACATGGGGCAGT
CAGAAACAGC-3=), E1R (5=-TTCAATTCTCATGGTCACATCT-3=),
and E0R (5=-TTTGAACATGTGCTGGGTTGTG-3=). The following cycling conditions for Phusion Taq were used with 1 l of cDNA in a 50-l
PCR mixture: 98°C for 30 s; 30 cycles of denaturing at 98°C for 10 s,
annealing at 60°C for 30 s, and extension at 72°C for 1 min; and a final
extension of 72°C for 10 min. Round 2 nested amplification was performed using 2 l of round 1 product in a 50-l reaction mixture using
the same cycling conditions. The following cycling conditions for Platinum Taq were used with 1 l of cDNA in a 50-l PCR mixture: 95°C for
5 min; 30 cycles of denaturing at 94°C for 30 s, annealing at 60°C for 30 s,
and annealing at 72°C for 1 min 30 s; and a final extension at 72°C for 7
min. Round 2 nested amplification was performed using 2 l of round 1
product in a 50-l reaction mixture using the same PCR conditions. PCR
products were visualized through running on a 1% ethidium bromide gel,
and excised bands were purified using a Geneclean II kit (MP Bio). Purified PCR products from Phusion PCR were ligated into a pCR-Blunt II
TOPO vector (Invitrogen), and purified PCR products from Platinum
Taq PCR were ligated into either a pCR4-TOPO vector (Invitrogen) or a
pGEMT-Easy vector (Promega) and analyzed by DNA sequencing (Macrogen USA).
Cell transfections and luciferase assays. Transfection of Vero-Cre
and RAW 264.7 cells was done in 6-well plates, where at 1 day prior to
transfection, cells were plated at 2 ⫻ 105 cells per well in cMEM. Transfection mixtures were prepared using 2.5 g of reported plasmid and 5 ng
of pHR-LUC Renilla luciferase vector as a transfection control. Transfections were performed using LT-1 transfection reagent (Mirus) according
to the manufacturer’s instructions. pGL4.13[Luc] was used as a positive
control, pGL4.10[luc] was used as a negative control, and the green fluorescent protein pMaxGFP was used to determine transfection efficiency.
For assay mixtures treated with IFN-␣, 5,000 IU/ml was added at 24 h
posttransfection, and all cells were collected at 48 h posttransfection and
lysed. All dual-luciferase assays were performed using a dual-luciferase kit
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Orf50F65040_65089 and the reverse external primer from reaction
two Orf50R66641_66690. The resulting product, containing a 50-bp
deletion within the distal promoter region of the Orf50 locus, was gel
purified and used as the template for a second overlapping PCR using
the same conditions as the first PCR but this time targeting a deletion
within the proximal promoter region. The primers used for reaction
one amplification were forward primer Orf50F65040_65089 (5=-CTT
AAAGGAGGAGCTGTTGGCAGTGCTTGCTGAAAATACCTCATC
AAACT-3=) with reverse primer Orf50PpKORHindIII (5=-GAACAGT
ATGAGAAAAAGCTTCAGGGAATTTTGTTATGTGC-3=), and the
primers used for reaction two amplification were reverse primer
Orf50R66641_66690 (5=-CCTCAGCCTTTGAAGGGACATTTCATG
ACTCATGTAGGAGGAGCTACCAG-3=) with forward primer
Orf50PpKoFHindIII (5=-CCCTGGAATCATAGAAAGCTTTTTCTCAT
ACTGTTCCTTTT-3=). As before, 2 l of each round one amplification
product was used as the template for a round two reaction using
the same external primers as before, Orf50F65040_65089 and
Orf50R66641_66690. The resulting PCR product was gel purified and
now contained a 50-bp deletion within the Orf50 distal promoter region,
a 70-bp deletion within the Orf50 proximal promoter region, and 50 bp of
homology to the region directly external to the MHV68.⌬50galK
Orf50galK region. A WT Orf50 PCR product containing the 50-bp homology arms was also generated in order to create an Orf50 marker rescue
of the MHV68.⌬50galK parent BAC to ensure that no spontaneous mutations had arisen. This mutant or WT PCR product was electroporated
into SW102/MHV68.⌬50galK and after recombination was selected
on minimal medium plates containing glycerol and 2-deoxy-Dgalactose. The colonies were then screened by colony PCR using primers
ORF50E0F
(5=-CACAACCCAGCACATGTTCAAACAT-3=)
and
ORF50E0R (5=-CTGTGTCTCACTGAAAACACTC-3=). Colonies were
then further verified by restriction digestion using the HindIII diagnostic
sites, as well as confirmation by PCR of the ORF50 region and DNA
sequencing of the PCR product (Macrogen Sequencing). The integrity of
the nonmutated BAC was confirmed through further restriction endonuclease digestion using PstI and EcoRI. Restriction endonuclease digests
were then subjected to Southern blotting analyses using a PCR-generated
fragment spanning the entire Orf50 region as the probe.
Production of virus. Both the G50DblKo and G50DblKo.MR viruses
were generated from yellow fluorescent protein (YFP) BAC (19). In order
to ensure proper viral growth of the G50DblKo virus, a protocol was
developed in which the virus would be passaged and titers determined in
the absence of type I interferons. Both mutant and marker rescue BACs
were transfected using LT-1 transfection reagent (Mirus) into Vero cells
expressing Cre-recombinase (Vero-Cre cells). When cells reached 70%
cytopathic effect (CPE), cells and supernatants were collected and freezethaw lysed three times. The resulting stock was used to infect new VeroCre cells to ensure the excision of the BAC. At 70% CPE, cells and supernatants were once again collected, lysed, and used to infect large quantities
of Vero-Cre cells to scale up viral stocks. Viral titers were determined as
described below.
Tissue culture. Mouse embryonic fibroblasts (MEFs) and NIH 3T12,
Raw264.7, and Vero-Cre cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal calf serum, 2 mM
L-glutamine, 100 U of streptomycin per ml, and 100 U of penicillin per ml
(cMEM). Vero-Cre cells used for virus generation were passaged with the
addition of 300 g of hygromycin B/ml. Cells were maintain at 37°C in a
tissue culture incubator with 5% CO2. MEFs were obtained from C57BL/6
mouse embryos, and IFN-␣/␤R⫺/⫺ MEFs were obtained from 129S2/
SvPas.IFN-␣/␤R⫺/⫺ mice as previously described (20).
Growth curves, plaque assays, and viral titers. Growth curves were
performed using Vero-Cre, 3T12, IFN-␣/␤R⫺/⫺ MEF, or C57BL/6 MEF
cells plated in six-well plates at a concentration of 1.75 ⫻ 105 cells per well
24 h prior to infection. The cellular concentration after 24 h was determined, and viral stocks were diluted to a 200 l volume in cMEM at
multiplicities of infection (MOIs) of 0.01, 0.1, and 10. These inoculums
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from latency were performed as previously described (20, 21). Briefly, to
determine the frequency of viral genomes, splenocytes or PECs were serial
diluted in 96-well plates and subjected to protease K digestion. After digestion, cells were used in a two-round nested PCR using primers found in
the G50 region. PCR products were resolved on a 2% agarose gel and
analyzed. To determine the frequency of infected cells reactivating from
latency, splenocytes or PECs were counted and diluted in cMEM. Cells
were then plated as serial 2-fold dilutions onto an MEF or IFN-␣/␤R⫺/⫺
MEF monolayer in 96-well plates. In parallel, mechanically disrupted cells
also were plated as a serial 2-fold dilution to detect any preformed infectious virus. At 21 days postplating, each well was assessed for CPE and
scored as a percentage. For both limiting-dilution PCR and limiting-dilution reactivation, the Poisson distribution was used to determine frequencies.
Mice, infections, and tissue preparation. Female C57BL/6 mice (The
Jackson Laboratory) and 129S2/SvPas.IFN-␣/␤R⫺/⫺ mice 6 to 8 weeks of
age were maintained at Emory University. Mice were housed under sterile
conditions and maintained in accordance with Emory University School
of Medicine (Atlanta, GA), as well as all federal guidelines. C57BL/6 or
129S2/SvPas.IFN-␣/␤R⫺/⫺ mice were infected intranasally (i.n.) with
1,000 PFU of WT-YFP, G50DblKo, or G50DblKo.MR virus in 20 l
cMEM following isoflurane anesthetization. 129S2/SvPas.IFN-␣/␤R⫺/⫺
mice were weighed at the time of infection, and weight was monitored
daily; mice were sacrificed if they lost 20% of their original body weight.
C57BL/6 mice were also infected intraperitoneally with 1,000 PFU of
WT-YFP, G50DblKo, or G50DblKo.MR virus in 200 l cMEM. With
both routes of infection, C57BL/6 mice were sacrificed at day 18 postinfection or at 7 days postinfection for lung titers. Surviving 129S2/
SvPas.IFN-␣/␤R⫺/⫺ mice were sacrificed at day 28 postinfection. Mice
were sacrificed by isoflurane and cervical dislocation. PECs were collected
by peritoneal lavage using 10 ml cMEM, spleens were harvested, and
splenocytes were prepared by manual homogenization, while lungs were
harvested and prepared by mechanical bead disruption using 1.0-mm
silica beads. Splenocytes were treated with Tris-ammonium chloride to
eliminate red blood cells. All prepared cells were counted using a Cellometer Auto T4 (Nexcelom) and immediately used for lung titer, reactivation, or genome analysis. Cells not used immediately were stored in
cMEM–10% dimethyl sulfoxide at ⫺80°C.
Immunoblotting. Infections were carried out as described above for
growth curves. At 24, 48, and 72 h postinfection, cells were harvested,
washed with 1⫻ phosphate-buffered saline (PBS), and then resuspended
in 40 l of lysis buffer containing 150 mM NaCl, 50 mM Tris-HCl, 1 mM
EDTA, and 0.1% Triton X-100 supplemented with 1 mM NaF, 1 mM
Na3VO4, and an EDTA-free protease inhibitor tablet (Roche). Protein
quantifications were carried out using a DC protein assay (Bio-Rad). For
all blots, 30 g of protein was mixed with 6⫻ SDS loading buffer, boiled
for 5 min at 100°C, and resolved by SDS-PAGE. SDS-polyacrylamide gels
were transferred to a nitrocellulose membrane using a semidry apparatus
(Bio-Rad). After transfer, membranes were blocked in 5% milk in Trisbuffered saline (TBS)–Tween for 1 h at room temperature. After 1 h,
membranes were washed three times with TBS-Tween, and the primary
antibody rabbit anti-MHV68 RTA (22) diluted 1:1,000 in blocking buffer
was added and left overnight with rocking at 4°C. Following overnight
incubation, the primary antibody was removed and the membrane
washed three times with TBS-Tween. The membrane was then incubated
with the secondary donkey anti-rabbit antibody (Jackson Immunoresearch) diluted 1:2,000 in blocking buffer for 1 h at room temperature.
This was followed by three additional washes with TBS-Tween. The blot
was then developed using SuperSignal West Pico chemiluminescent substrate (Pierce). Membranes were stripped using Restore PLUS Western
blot stripping buffer (Thermo Scientific). Membranes were then subjected to the same protocol using the primary mouse monoclonal ␤-actin
antibody (Sigma) at 1:5,000 and the secondary donkey anti-mouse antibody (Jackson Immunoresearch) at 1:5,000. Membranes were also subjected to the same protocol to blot for v-cyclin, where primary rabbit
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(Promega) according to manufacturer’s instructions. Single-luciferase assays were performed using lab-made luciferase agent (1.5 mM HEPES
[pH 8], 80 M MgSO4, 0.4 mM dithiothreitol [DTT], 2 M EDTA, 10.6
M ATP, 5.4 M coenzyme A, and 9.4 M beetle Luciferin), where 10 l
of cell lysate was added to 50 l of luciferase agent. Both single- and
dual-luciferase assays were read using a TD-20/20 luminometer (Turner
Biosystems). All transfections were repeated in triplicate, and results are
presented as a fold ratio over that for empty pGL4.10 vector.
Reporter plasmids and cloning. DNA from the Orf50 region was amplified from the MHV68 WT BAC and cloned into a luciferase reporter
construct. Phusion Taq (NEB) was used with the following cycling parameters for all amplifications: 95°C for 5 min; 30 cycles of denaturing at 94°C for
30 s, annealing at 58°C for 30 s, and extension at 72°C for 30 s; and a final 72°C
extension for 10 min. Overlapping PCR was used with the following primers
to generate E0 luciferase promoter constructs with 50-bp deletions. Round
one PCR used forward primer E0-250F (5=-GATCGGCTAGCTTAATCCTA
TATGGAGAT-3=) with the following reverse primers: del 65822-65872R (5CATGTCTCAGCCAACAGCTCGACACTTCGAGTACC-3=), del 6577265822R (5=-AGAATAATGGACTCCAGCTGAGTCATAGAACATAC-3=),
and del 65722-65772R (5=-GCACGTATTGCTGAAAAGGAATGATCAGG
AATTCT-3=). Reverse primer E0ATGR (5=-GATCGAAGCTTGTGCTGGG
TTGTGAAG-3=) was used with the following forward primers: del 6582265872F (5=-GGTACTCGAAGTGTCGAGCTGTTGGCTGAGACATG-3=),
del 65772-65822F (5=-GTATGTTCTATGACTCAGCTGGAGTCCATTAT
TCT-3=), and del 65722-65772F (5=-AGAATTCCTGATCATTCCTTTTCA
GCAATACGTGC-3=). After round one PCR, 2 l of PCR products from del
65822-65872, del 65772-65822, and del 65722-65772 was used as the template
for a round two PCR following the same cycling conditions as for round one
with forward primer E0-250F and reverse primer E0ATGR. These secondround PCR products were gel purified and cloned into pCR-Blunt (Invitrogen) for vector shuttling and sequence confirmation. The pCR-Blunt plasmid
was then cut with HindIII and NheI to excise the E0 fragments, and the
luciferase reporter construct pGL4.10[luc2] (Promega) was also digested with
HindIII and NheI. The digested E0 products and pGL4.10[luc2] vector were
then gel purified, resuspended in Tris-EDTA (TE), and ligated together using
T4 DNA ligase (NEB) overnight at 16°C. Ligation products were transformed
into Top 10 chemically competent cells, and colonies were screened for the
presence of correctly oriented E0 pGL4.10[luc2] vectors through restriction
digestion and DNA sequencing. Clones containing correct E0 deletion and
expression were cultured, and plasmid DNA was isolated using an Endofree
Maxikit (Qiagen). The process of generating Orf50 N3 and N4/N5 promoter
luciferase constructs followed a method similar to that described above, with
only a single PCR amplification required to generate 1,000-bp-long PCR fragments. The primers used for this single PCR were as follows: the reverse
primer N4_N5RBgl2 (5=-CGATAGATCTAAGCCGTGGTCAGCAGGT-3=)
was used with the forward primer N4_N5F1000Nhe1 (5=-AGTCGCTAGCA
ATCGTCCGGGGGGTTAA-3=), and the reverse primer N3RBgl2 (5=-CGA
TAGATCTAGCCTGGGGCATAGTTCTT-3=) was used with the forward
primer N3FNhe1 (5=-AGTCGCTAGCTCAGGATGCAGTTAAGCA-3=).
These products were gel purified, shuttled through pCR-blunt, digested with
NheI and BglII, and then ligated into pGL4.10[luc2]. The generation of the
proximal promoter expression constructs followed the same protocol as described above. Forward primer ProxPromF (5=-GATCGCTAGCTCTTTAT
AGGTACCAGGGAA-3=) was used with reverse primer ProxPromR (5=-TA
GCAGATCTGGTCACATCTGACAGAGAAA-3=) to generate the 410-bp
proximal promoter luciferase construct. Overlapping PCR using forward
primer ProxPromDelF (5=-CCCTGGAATCATAGATTTCTCATACTGTTC
CTTTT-3=) with primer ProxPromR and reverse primer ProxPromDelR (5=GAACAGTATGAGAAATCTATGATTCCAGGGAATTT-3=) with primer
ProxPromF was used to generate the proximal promoter 70-bp deletion construct. Digestion, ligation, and purification also followed the same protocol as
described above.
Limiting-dilution PCR and limiting-dilution reactivation assays.
Limiting-dilution PCR to determine the frequency of viral genomes and a
limiting-dilution CPE assay to determine the number of cells reactivating
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Reporter constructs were generated within the context of the 250-bp promoter through overlapping PCR. The 50-bp E0 promoter mutants were
cloned into the pGL4.10[luc] luciferase report construct. RAW 264.7 cells
were cotransfected with pGL4.10[luc] luciferase report constructs containing 50-bp deletions as illustrated and phRL-Luc (Renilla luciferase). RAW
264.7 cells were stimulated with LPS (5 g/ml) at 24 h after transfection, and at
48 h after transfection luciferase assays were performed. Data are presented as
the fold difference in the ratio of firefly to Renilla luciferase versus the
pGL4.10[luc] empty vector control. The data were compiled from 3 independent transfections, each done in triplicate. Standard errors of the means are
shown.

monoclonal v-cyclin antibody was used at 1:2,000 overnight and the secondary donkey anti-rabbit antibody (Jackson Immunoresearch) was used
at 1:2,000 for 1 h at 4°C.

RESULTS

Characterization of the Orf50 distal promoter activity in vitro.
We previously reported the generation and characterization of a
gene 50 proximal promoter knockout virus (G50pKo), which led
to the identification of an additional promoter upstream of the
proximal promoter, now referred to as the distal promoter (16).
The additional distal promoter drives the expression of a new exon
(E0), and the core promoter region corresponds to the first 250 bp
upstream of the E0 transcriptional start site. To further characterize the activity of this newly defined promoter region, we generated serial 50-bp deletions (⌬65672-65722, ⌬65722-65772,
⌬65772-65822, and ⌬65822-65872) in the core 250-bp distal promoter region (Fig. 2). These serial 50-bp deletion fragments were
cloned into the pGL4.10 luciferase reporter vector, and the resulting reporter plasmids transfected into RAW 264.7 cells. It was
previously reported that the gene 50 distal promoter was most
active in RAW 264.7 cells with the addition of lipopolysaccharide
(LPS) (16).
Luciferase assays confirmed the previous finding that the
250-bp distal promoter region drives significant gene expression,
⬃30-fold over that with empty vector in the RAW 264.7 cells with
the addition of LPS (Fig. 2). Notably, deletion of the sequences
from bp 65672 to 65722 resulted in a substantial increase in promoter activity over that with empty vector (⬃4.6-fold above that
observed with the full-length 250-bp promoter construct), indicating the presence of negative cis elements in this region. Similarly, deletion of the sequences from bp 65822 to 65872 also resulted in a strong enhancement of activity (⬃40-fold above that
observed with the full-length 250-bp promoter construct). This
would indicate that both of these regions play an important role in
limiting gene 50 transcription. Conversely, deletion of the sequences from bp 65772 to 65822 resulted in nearly complete si-
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FIG 2 Promoter deletions within the MHV68 E0 250-bp promoter region.

lencing of distal promoter activity (ca.16-fold below that observed
with the full-length 250-bp promoter construct), arguing that essential positive cis elements map to this region. Therefore, we
chose to delete the latter region in the context of the viral genome
to ablate distal gene 50 promoter activity.
Generation of a recombinant MHV68 lacking both the proximal and distal gene 50 promoters. With the identification of a
second promoter driving RTA expression, we set out to generate a
gene 50 functionally null virus through the deletion of both the
distal and proximal promoters. We targeted the promoter regions
because previous attempts to propagate gene 50 null viruses harboring mutations within the coding sequence were confounded
by the generation of wild-type revertant viruses upon growth on
complementing cell lines (i.e., recombination of wild-type gene 50
sequences into the viral genome) (23). Since the gene 50 null mutants grow slowly on complementing cell lines, any wild-type revertant virus quickly overtakes growth of the gene 50 null virus
and ends up dominating the viral stock generated. In a previous
attempt to overcome this problem, we deleted a 183-bp region of
the proximal gene 50 promoter (the only known gene 50 promoter at the time), and it was the analysis of this mutant virus that
led to the identification of the distal gene 50 promoter (16). Notably, the deletion introduced into the viral genome to generate
the proximal promoter mutant virus (G50pKo) also deleted the
splice acceptor site utilized by the distal gene 50 promoter-driven
gene 50 transcript. To circumvent this issue, we redesigned the
proximal promoter deletion to introduce a 70-bp deletion (corresponding to the region immediately upstream of the exon 1 transcript at coordinates bp 66412 to 66482), leaving the splice acceptor site intact (Fig. 3A). This new gene 50 proximal promoter
knockout virus (G50PpKo) was used as the backbone for the generation of the G50DblKo virus.
To disrupt the distal gene 50 promoter, we targeted the 50-bp
region from bp 65772 to 65822, which was determined to be essential for promoter activity in the in vitro analyses carried out in
the RAW 264.7 cell line (Fig. 2). To confirm the generation of the
G50DblKo virus, we sequenced the areas of interest to ensure that
the desired deletions were present in the viral genome (data not
shown). To further confirm that the virus was intact and that the
deletions were inserted into the gene 50 locus, as well as the absence of spontaneous rearrangements and insertions in the viral genome, we digested the mutant BAC with the restriction endonucleases HindIII, PstI, and EcoRI. Notably, in the process of generating
the desired deletions, we introduced diagnostic HindIII sites (Fig. 3B
and C). HindIII digestion of the G50DblKo mutant yielded the
three expected digestion fragments (590 bp, 874 bp, and 1,059 bp),
while HindIII digestion of wild-type virus and the marker rescue
BAC DNAs resulted in the expected 2,643-bp product. To further
assess the presence of the deletions in the gene 50 locus, we performed Southern blotting of the HindIII-digested BAC DNAs
(Fig. 3C). We probed the blot with a 1,651-bp probe corresponding to genome coordinates from bp 65040 to 66690, which hybridized to all three fragments generated. Notably, the band intensities
varied and were dependent on the extent that the probe overlapped with the fragments generated. Importantly, the wild-typesized fragment was absent from the G50DblKo and G50PpKo viral
genomes, eliminating the possibility of a genome duplication of
the gene 50 locus or recombination of the targeting sequences
into another region of the viral genome. The final confirmation
that the mutant generated was specific to the area of interest was

Alternative MHV68 Gene 50 Transcripts

the generation and confirmation of the G50DblKo.MR and
G50PpKo.MR viruses, in which the Orf50 GalK region was replaced with the WT Orf50 region. These marker rescue viruses
were all analyzed by sequencing, restriction enzyme digestion, and
Southern blotting, and all three methods confirmed reversion
back to WT virus. To ensure that the phenotypes observed with
the G50pDblKo virus were in fact the result of the desired mutations, this process was conducted four independent times, resulting in the isolation of four independently generated mutant
clones. These clones were used throughout the experiments interchangeably, and each experiment was conducted using at least two
if not all of the clones. The use of multiple independent clones, in
conjunction with the G50pDblKo.MR virus, makes it very unlikely that the observed phenotypes were the result of spontaneous
mutations arising elsewhere within the genome.

May 2014 Volume 88 Number 10

Replication of the MHV68 G50DblKo mutant, but not wildtype MHV68, is inhibited by type I interferons. To generate the
G50DblKo virus, the mutated BAC was first transfected into Vero
cells expressing Cre recombinase (Vero-Cre cells) (24) to excise
the BAC from the MHV68 BAC. The removal of the BAC sequence is necessary since virus containing BAC sequences is significantly attenuated in vivo (25). Upon successful removal of the
BAC in Vero-Cre cells, viral stocks are generated by growth on
murine NIH 3T12 cells (24). Surprisingly, Vero-Cre cells transfected with the G50DblKo BAC DNA supported growth of this
mutant, indicating that the proximal and distal gene 50 promoters
are not required for RTA expression. However, upon low-MOI
infection of NIH 3T12 fibroblasts with the resulting viral stock
generated from growth in Vero-Cre cells, we failed to observe any
replication of the G50DblKo mutant. To further investigate this
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FIG 3 Generation of MHV68 G50DblKo and G50DblKo.MR viruses. (A) Schematic diagram of alternatively initiated gene 50 transcripts. The locations of the
known proximal and distal gene 50 promoters are shown. The two hatched areas depict the regions deleted within the mutant G50DblKo virus: a 50-bp deletion
extending from bp 65772 to 65822 in the distal promoter region and a 70-bp deletion extending from bp 66412 to 66482 in the proximal promoter region. There
are two HindIII sites in the WT genome located at bp 64898 and 67541; the G50DblKo virus has two additional HindIII sites introduced within the deletions,
located at bp 65797 and 66447. The splicing of E1 to E2 driven by the proximal promoter and the splicing of E0 to E1 to E2 driven by the distal promoter are
shown. (B) HindIII restriction endonuclease digests of G50DblKo, G50PpKo, G50DblKo.MR, G50PpKo.MR, G50GalK, and WT-YFP BAC. The diagnostic
restriction fragments are depicted (). (C) Southern blot of the HindIII digest shown in panel B using a probe specific for the Orf50 region. Three unique
digestion fragments are shown for the G50DblKo virus, the WT and MR rescue viruses are shown to be the same, and the galK parent fails to hybridize the Orf50
probe due to the Orf50 region replacement with the G50PpKo cassette.
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phenomenon, multistep growth curves were performed on both
NIH 3T12 and Vero-Cre cells (Fig. 4). Consistent with the initial
analyses, the G50DblKo mutant was able to grow in Vero-Cre
cells, exhibiting only a mild replication defect (Fig. 4B), indicating
that both the proximal and distal gene 50 promoters are dispensable for RTA expression in these cells. However, we failed to observe any growth of the G50DblKo mutant on NIH 3T12 fibroblasts (ca. a 4- to 5-log defect in viral titers between the marker
rescue virus and the G50DblKo mutant at late times postinfection) (Fig. 4A).
Since a major difference between Vero cells and NIH 3T12
fibroblasts is that Vero cells lack the ability to generate type I
interferons, we assessed whether a type I IFN response can block
replication of the G50DblKo mutant virus. We infected mouse
embryo fibroblasts (MEFs) generated from C57BL/6 mice with
the G50DblKo virus, and once again we failed to see efficient replication (Fig. 5A). The G50DblKo virus exhibited nearly a 4-log
defect in viral titers at late times postinfection. To determine
whether type I interferons were responsible for this large defect,
we infected MEFs generated from 129S2/SvPas.IFN-␣/␤R⫺/⫺
mice. Similar to the results obtained in Vero cells, the inability of
the MEFs from mice lacking the IFN-␣/␤ receptor to respond to a
type I IFN response rescued the replication defect seen in the
C57BL/6 MEFs (Fig. 5B). Notably, in the 129S2/SvPas.IFN-␣/
␤R⫺/⫺ MEFs, the G50DblKo virus replication was indistinguishable from that of wild-type virus (Fig. 5B). To directly examine the
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FIG 4 G50DblKo virus replicates in vitro in Vero-Cre cells but fails to replicate
in NIH 3T12 fibroblasts. (A) Multistep growth curve of NIH 3T12 cells infected with an MOI of 0.1. Cells were infected with G50DblKo, G50DblKo.MR,
and WT-YFP viruses and collected for viral titer analysis at the indicated times
postinfection. (B) Multistep growth curve of Vero-Cre cells infected at an MOI
of 0.1. Cells were also infected with G50DblKo, G50DblKo.MR, and WT-YFP
viruses and collected for viral titer analysis at the indicated times postinfection.

impact of type I IFNs on replication of the G50DblKo mutant, we
compared virus replication in Vero cells in the absence and presence of IFN-␣. Vero-Cre cells were pretreated with IFN-␣ and
then treated every 24 h postinfection. Cells that were not treated
with IFN-␣, as seen before, showed normal growth and kinetics of
the G50DblKo virus, similar to those of WT and G50DblKo.MR
viruses (Fig. 5C). However, adding IFN-␣ severely inhibited replication of the G50DblKo mutant (Fig. 5D).
These analyses revealed an impact of type I interferons on in
vitro replication of MHV68 (although it has previously been
shown that acute viral titers in the lungs of IFN-␣/␤R⫺/⫺ mice are
significant higher than those in wild-type mice and that the absence of a type I IFN response renders mice highly susceptible to
lethal MHV68 infection [26–28]). These analyses also reveal that,
despite replication of the G50DblKo virus being attenuated in the
presence of a type I IFN response, there appears to be little or no
replication defect in comparison to wild-type virus when a type I
interferon response is absent, due to either the lack of the IFN␣/␤R or the absence of type I IFN expression. In addition, these
analyses demonstrate that despite the deletion of the known gene
50 promoters, the G50DblKo mutant is replication competent
under some experimental conditions, suggesting that there are
alternative mechanisms for expression of the essential immediate
early RTA.
Notably, upon higher-MOI infections, although there was a
partial rescue of the G50DblKo growth defect, this mutant still
exhibited a pronounced growth defect (Fig. 6A). Consistent with
the observed growth defect, we observed a small-plaque phenotype (Fig. 6C), which was observed with 4 independently derived
G50DblKo mutant BAC clones, making it unlikely that any of the
observed phenotypes are the result of secondary mutations in the
viral genome. However, when we examined the levels of RTA protein as a function of time postinfection, we observed a faster kinetics and higher levels of RTA at early times postinfection (Fig.
6B, 8-hour time point). This correlated with higher levels of the
v-cyclin expression as well at 8 hours postinfection (Fig. 6B). This
argues that the defect in virus replication is not directly attributable to failure to express RTA protein, although it does suggest
that entry into the lytic cycle may be dysregulated and that this
could lead to a defect in virion production.
Identification of three additional gene 50 transcripts driven
by 2 promoters mapping upstream of the distal gene 50 promoter. We have previously shown that transcription of MHV68
gene 50 is driven by two distinct promoters: (i) the proximal promoter, encoding a short 288-bp exon, E1, which splices to the
large 1,800-bp exon, E2 and (ii) the distal promoter, which encodes a short 181-bp exon, E0, which splices to E1, which in turn
splices to E2 (6, 12, 16) (Fig. 1). We further showed that this
organization of gene 50 transcription was conserved in both EBV
and KSHV (16). The unexpected ability of the G50DblKo mutant
to replicate under some experimental conditions indicated that
there must exist alternative mechanisms for driving gene 50 transcription, since RTA is known to be absolutely required for virus
replication (this has been shown for EBV, KSHV, and MHV68)
(23, 29–32). To determine if this hypothesis was indeed correct,
we performed 5= RACE analysis of RNAs from Vero-Cre, RAW
264.7, and IFN-␣/␤R⫺/⫺ MEFs infected with either wild-type
MHV68 or the G50DblKo mutant. From this analysis, we were
able to detect three previously unidentified gene 50 transcripts

Alternative MHV68 Gene 50 Transcripts

which initiated from two distinct upstream transcription initiation sites (Fig. 7).
The three additional transcripts were identified in all three cell
types examined and also were identified in both wild-type
MHV68- and G50DblKo virus-infected cells. It is important to
note that the 5= RACE analyses conducted using the G50DblKo
virus failed to detect the presence of any E1-E2 or E0-E1-E2 transcripts, further confirming that G50DblKo is indeed a true knock-

FIG 5 G50DblKo virus fails to replicate in vitro when IFN-␣ is present. (A)
Multistep growth curve of C57BL/6 mouse embryonic fibroblasts (MEFs) infected with G50DblKo or WT-YFP virus at an MOI of 0.01. (B) Multistep
growth curve of 129S2/SvPas.IFN-␣/␤R⫺/⫺ mouse embryonic fibroblasts
(IFN-␣/␤R⫺/⫺ MEFs) infected with G50DblKo or WT-YFP virus at an MOI of
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0.01. (C) Multistep growth curve of Vero-Cre cells infected with G50DblKo,
G50DblKo.MR, or WT-YFP virus at an MOI of 0.1. (D) Multistep growth
curve of Vero-Cre cells, treated with IFN-␣ (10,000IU/ml) at the time of infection and every 24 h thereafter, infected with G50DblKo, G50DblKo.MR, or
WT-YFP virus at an MOI of 0.1. All cells were collected at the times indicated,
and experiments were repeated at least in triplicate.
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FIG 6 Single-step growth analyses of the G50pDblKo mutant and analysis of
the kinetics of RTA expression. (A) Single-step growth curve of G50pDblKo or
WT-YFP virus in NIH 3T12 fibroblasts infected at an MOI of 10. (B) Western
blot staining for RTA, v-cyclin, and ␤-actin expression from the same cells
used in the single-step growth curve shown in panel A. (C) Representative
sample of the small-plaque phenotype exhibited under all experimental conditions when using different G50pDblKo clones.
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out of the proximal and distal gene 50 promoters. The first new
exon, which we have termed N3, is a 330-bp extension of the
previously characterized E0 exon. This new N3 exon is 511 bp long
and maps to coordinates bp 65579 to 66090 in the MHV68 genome. The 3= end of this exon is identical to the 3= end of the E0
exon. Like E0, this newly identified N3 exon splices to the E1 exon,
leading to removal of a 419-bp intron, which in turn splices to the
E2 exon, removing an 865-bp intron (Fig. 7). The second new
exon, which we have termed N4, is a 743-bp extension of the E0
exon. The N4 exon map to bp 65166 to 66090 in the MHV68
genome and is 924 bp long (Fig. 7). The 3= end of this exon is also
identical to the 3= end of E0 and splices to the E1 exon and then to
the E2 exon. The final alternatively spliced transcript contains a
new exon, which we have termed N5, which is 216 bp long and
maps to bp 65142 to 65358 in the MHV68 genome (Fig. 7). This
new exon consists mainly of the 5= end of the newly identified N4
exon, with a 24-bp extension, indicating that the N4 and N5 exons
share a promoter region. However, unlike N4, which is an extension of E0, the N5 exon exhibits a completely unique splicing event
in which the 3= end at bp 65358 splices to E1, directly eliminating
a large 1,151-bp intron. Like the other known exons, the E1 exon
then splices to the E2 exon.
It is important to note that none of the newly identified exons
have been observed to splice directly to the E2 exon, but rather all
of them splice to the E1 exon, which contains the RTA translation
initiation codon. Thus, to date, there is no evidence for alternative
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RTA translation initiation sites. This, however, does not exclude
the possibility of unique splicing events from the newly identified
transcripts to a novel position within the E2 exon or elsewhere
within the viral genome. It should be noted that there are several
short ATG-initiated open reading frames within the newly identified exons, which may play an important role (i.e., encoding
novel viral gene products and/or interfering with RTA translation) (Fig. 7).
Neither the N3 promoter nor the N4/N5 promoter exhibits
sensitivity to IFN-␣, but RTA levels from the G50DblKo mutant
are diminished in the presence of a type I IFN response at low
MOI. The identification of alternative gene 50 transcripts provides a clear mechanism by which the G50DblKo virus is apparently able to generate sufficient levels of RTA to drive virus replication, at least in the absence of a type I IFN response. However, it
does not address the issue of why replication of the G50DblKo
mutant is suppressed by type I IFNs. To begin to address this issue,
we cloned 1,000-bp fragments immediately upstream of the 5=
ends of the N3 and N4/N5 transcripts into the pGL4.10 luciferase
reporter vector (Promega Biotech) and transfected the resulting
reporter constructs into Vero-Cre cells. While the N3 promoter
resulted in expression ⬃4-fold over that with empty vector, the
N4/N5 promoter resulted in slightly higher levels of luciferase
expression (⬃13-fold over empty vector) (Fig. 8). These data
demonstrate that the region immediately upstream of the newly
identified gene 50 transcripts exhibits modest promoter activity.
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FIG 7 RACE analyses reveal three additional G50 exons upstream of E0. RACE analyses were performed using cDNAs generated from WT-YFP- and G50DblKoinfected Vero-Cre, Raw 264.7, and IFN-␣/␤R⫺/⫺ MEFs at 24 and 48 h postinfection. 5= RACE analysis using reverse primers located in E2, E1, and E0 were used
in conjunction with the universal 5= RACE forward primer. All three experiments identified three additional exons upstream of E0: exon N3, representing a
330-bp extension of E0; exon N4, representing a 743-bp extension of E0; and exon N5, representing a small novel 216-bp exon. All three new exons follow
canonical splicing in which they splice to E1, which in turn splices to E2. Green arrows denote short ATG-initiated open reading frames that lie upstream of the
RTA-coding sequences, which are indicated in blue. The locations of the major open reading frames antisense to gene 50 are also shown. Red arrows denote
primers used in the 5= RACE analyses. The positions of the primers used were as follows: E2-1, bp 68095 to 68066; E2-2, bp 68051 to 68027; E1, bp 66530 to 66509;
and E0, bp 65930 to 65909.
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N5 exons. Vero cells were transfected with pGL4.10[luc] luciferase report constructs containing either 1,000 bp upstream of N3 or 1,000 bp upstream of the
N4/N5 exon. Vero cells were stimulated with IFN-␣ (10,000 IU/ml) at 24 h
after transfection, and at 48 h after transfection luciferase assays were performed. Data are presented as the fold difference of firefly luciferase activity
versus the pGL4.10[luc] empty vector control. The data represent triplicates of
at least three independent transfections.

To determine if the type I IFN-sensitive replication of the
G50DblKo mutant virus reflects type I IFN-mediated suppression
of gene 50 transcription from the G50DblKo mutant, we examined N3 and N4/N5 promoter activity in the presence of IFN-␣
treatment (Fig. 8). Since Vero cells fail to produce IFN-␣ but
retain the ability to respond to exogenously added IFN-␣ (Fig.
5D), IFN-␣ was added to the transfected Vero cells and promoter
activity assessed (Fig. 8). Similar luciferase assays of previously
identified Orf50 transfected promoters have shown them to be
sensitive to IFN-␥ (33). However, our analysis showed no evidence of IFN-␣ suppression of reporter gene activity, suggesting
that IFN-␣ inhibition of G50DblKo replication acts downstream
of gene 50 transcription. This is consistent with the absence of any
consensus IFN-stimulated response elements (ISREs) in the region upstream of the N3 and N4/N5 transcription initiation sites.
Since it appeared that the newly identified gene 50 promoters
are not sensitive to IFN-␣, we examined the levels of RTA protein
expression in wild-type MHV68- and G50DblKo mutant-infected
cells. To assess RTA levels following infection, immunoblots were
probed at several time points following low-MOI infection (Fig.
9). Consistent with the observed replication defect of the
G50DblKo mutant virus in either NIH 3T12 fibroblasts or
C57BL/6 MEFs, RTA levels were lower at all time points assessed
(Fig. 9A and B). However, equivalent levels of RTA were detected
in 129S2/SvPas.IFN-␣/␤R⫺/⫺ MEFs infected with either wildtype MHV68 or the G50DblKo mutant virus. It is also notable that
RTA was readily detectable by 24 h postinfection of either
C57BL/6 MEFs or 129S2/SvPas.IFN-␣/␤R⫺/⫺ MEFs but not NIH
3T12 fibroblasts (compare Fig. 9B and C with A). We have previously noted that MEFs are more sensitive to MHV68 infection as
determined by a limiting-dilution CPE analysis which can detect
between 0.1 and 0.2 PFU of virus with titers determined on NIH
3T12 fibroblasts (34), and this likely accounts for the earlier detection of RTA expression (i.e., effectively a higher-MOI infection).
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FIG 9 Immunoblot analyses of RTA protein expression levels in WT- and
G50DblKo-infected NIH 3T12 fibroblasts, C57BL/6 MEFs, and 129S2/
SvPas.IFN-␣/␤R⫺/⫺ MEFs. (A) NIH 3T12 cells were infected with wild-type
MHV68 or the G50DblKo mutant at an MOI of 0.1, and cells were harvested at
24, 48, and 72 h postinfection. Cells were lysed, and 30 g of protein was used
for the immunoblot analyses to assess RTA expression levels. (B and C) MEFs
prepared from either C57BL/6 (B) or 129S2/SvPas.IFN-␣/␤R⫺/⫺ (C) were
infected at an MOI of 0.1, and cells were harvested at 24, 48, and 72 h postinfection. As for panel A, cells were then lysed and 30 g of protein used in a
immunoblot analysis to detect RTA expression levels. All immunoblots were
stripped and then reprobed for ␤-actin levels to ensure equal protein loading.

When looking at RTA levels from growth curves following
high-MOI infection, in which there is a partial rescue of the
G50DblKo growth defect (Fig. 6A), the early kinetics and expression of RTA appear to be at similar or slightly higher levels than in
WT infection (Fig. 6B). RTA was detectable at significant levels at
8 h postinfection in the G50DblKo virus-infected fibroblasts,
while RTA was detectable at 12 h postinfection in WT virus-infected fibroblasts. However, the levels of RTA begin to wane by 24
h postinfection with the G50DblKo mutant, while WT RTA continues to increase. This may help explain the partial rescue of the
growth phenotype at high MOI. Notably, the induction of v-cyclin
expression parallels that of RTA expression for both the WT and
G50DblKo infections. These results demonstrate that despite an
increased sensitivity to type I interferons, as well as a partial
growth defect at high MOI, the G50DblKo virus is able to generate
functional RTA capable of driving transcription as well as launching expression of downstream viral targets such as v-cyclin.
The G50DblKo mutant establishes latency in the spleen and
in PECs but is severely impaired for virus reactivation. To assess
infection in mice with the G50DblKo mutant, we initially infected
C57BL/6 mice intranasally with 1,000 PFU of either the
G50DblKo virus, WT MHV68, or the G50DblKo.MR virus. We
then assessed viral latency at day 18 postinfection, the peak of
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FIG 8 Promoter activity in the region immediately 5= to MHV68 N3, N4, and

Wakeman et al.

latency in the spleen, and determined both the frequency of
splenocytes harboring the viral genome and the frequency of
splenocytes able to reactivate from latency. Splenocyte reactivation was determined by the previously described limiting-dilution
CPE assay (20) modified by plating splenocytes on IFN-␣/␤R⫺/⫺
MEF monolayers to ensure the ability to detect any reactivated
G50DblKo mutant virus. The reactivation analyses revealed the
nearly complete absence of detectable reactivation of the
G50DblKo virus from splenocytes (Fig. 10A). In contrast, splenocytes harvested from wild-type virus-infected animals reactivated
at a frequency of 1 in 7,035 cells, while the frequency of reactivation from the G50DblKo.MR virus was 1 in 9,549 cells (Fig. 10A
and Table 1). No preformed infectious virus was detected in the
harvested splenocyte samples, as measured by mechanical disruption of the cells as previously described (20) (data not shown).
To determine if this failure to reactivate from splenocytes observed with the G50DblKo mutant virus was the result of a failure
to establish latency, limiting-dilution PCR was performed to determine the frequency of splenocytes harboring viral genomes
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(20). We observed that the frequency of splenocytes harboring
latent virus was roughly equivalent for the wild-type virus and the
G50DblKo.MR virus at 1 in 223 and 1 in 305 cells, respectively,
while the G50DblKo mutant virus was present in splenocytes at a
frequency of ca. 1 in 1,941 cells (Fig. 10B and Table 1). While the
frequency of viral genome-positive splenocytes in the G50DblKo
virus-infected animals was around 8.5-fold lower than that in the
wild-type virus-infected animals, these analyses demonstrate that
this mutant virus is able to get to the spleen and establish latency.
Thus, the lack of detectable reactivation of the G50DblKo mutant
reflects a significant defect in virus reactivation from B cells, the
dominant latently infected cell population in the spleen (19, 35).
We extended these analyses to address whether the inability of
the G50DblKo mutant virus to reactivate from splenocytes was
dependent on the route of inoculation and to assess latency and
reactivation from PECs. To do this we assessed virus reactivation
from splenocytes and PECs following intraperitoneal (i.p.) inoculation. C57BL/6 mice were infected by intraperitoneal inoculation with 1,000 PFU of G50DblKo, wild-type, or G50DblKo.MR
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FIG 10 G50DblKo virus exhibits a severe reactivation defect and a moderate latency defect in vivo. Female C57BL/6 mice were infected with 1,000 PFU i.n. (A
and B) or with 1,000 PFU i.p. (C and D). Splenocytes and PECs were harvested at 18 days postinfection and assessed for the establishment of latency and
reactivation from latency by limiting-dilution CPE and PCR assays. (A) Splenocytes from i.n. infections were plated in serial dilutions onto an IFN-␣/␤R⫺/⫺ MEF
monolayer, and at 21 days postplating wells were individually scored for CPE. The percentage of these wells was used to calculate the frequency of virally
reactivating cells. (B) Splenocytes from i.n. infections were plated in serial dilutions and subjected to nested PCR to detect gene 50 copies. The percentage of
genome-positive cells in each dilution was used to calculate the frequency of latency. (C) PECs from i.p. infections were plated in serial dilutions onto an
IFN-␣/␤R⫺/⫺ MEF monolayer, and 21 days postplating wells were individually scored for CPE. The percentage of these wells was used to calculate the frequency
of virally reactivating cells. (D) PECs from i.p. infections were plated in serial dilutions and subjected to nested PCR to detect gene 50 copies. The percentage of
genome-positive cells in each dilution was used to calculate the frequency of latency. For all reactivation assays (A and C), mechanically disrupted cells were plated
in parallel for each virus shown to control for preformed infectious virus, and all mechanically disrupted cells were negative for reactivation (data not shown).
Data are representative of at least two independent experiments consisting of 5 mice per group. Error bars indicate the standard error of the mean.
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TABLE 1 Summary of virus latency and reactivation
Splenocytes

PECs

Route

Day

Virus

Reactivation

Latency

Reactivation

Latency

C57BL/6

i.n.

18

WT
MR
DblKo
WT
MR
DblKo

1 in 7,035
1 in 9,549
Undetectable
1 in 36,107
1 in 65,962
1 in 422,863

1 in 223
1 in 305
1 in 1,941
1 in 388
1 in 1,047
1 in 627

NDa
ND
ND
1 in 17,782
1 in 14,417
Undetectable

ND
ND
ND
1 in 401
1 in 562
1 in 2,137

28

WTb
DblKo

1 in 77,624
1 in 52,420

1 in 131
1 in 133

ND
ND

ND
ND

i.p.

IFN␣␤R⫺/⫺
a
b

i.n.

ND, not determined.
Latency and reactivation were determined by pooling splenocytes from the 3 IFN␣␤R⫺/⫺ mice that survived wild-type MHV68 infection.

virus, and splenocytes and PECs were harvested at 18 days postinfection. We first examined the ability of the virus to reactivate
from splenocytes, as described above. As observed following intranasal inoculation, the G50DblKo mutant exhibited a large defect in reactivation, although a low but significant level of virus
reactivation was detectable (it was estimated by extrapolation that
the G50DblKo mutant reactivates at a frequency of 1 in 422,863
splenocytes) (Table 1). In these analyses, wild-type virus reactivated at a frequency of 1 in 36,107 splenocytes, while the
G50DblKo.MR virus reactivated at a frequency of 1 in 65,962
splenocytes (Table 1). Notably, the frequency of splenocytes reactivating virus at day 18 following intraperitoneal inoculation was
5- to 7-fold lower than that observed at the same time point following intranasal inoculation. This likely reflects faster kinetics of
establishment and contraction of splenic latency following intraperitoneal inoculation. This effect, coupled with the observed
low-level reactivation of the G50DblKo mutant, provides evidence that the route of inoculation does have an impact on reactivation of this mutant virus, which could be linked to better establishment of B cell latency (see discussion below). We then
assessed whether the observed reactivation defects correlated with
a defect in the establishment of latency. Notably, the 8.5-fold defect in establishment of latency in splenocytes observed following
intranasal inoculation was largely rescued following intraperitoneal inoculation (Table 1). The frequency of viral genome-positive cells in the splenocytes following intraperitoneal inoculation
was 1 in 388 cells for wild-type MHV68, 1 in 1,047 cells for the
G50DblKo.MR virus, and 1 in 627 cells for the G50DblKo mutant
(Table 1).
While nearly all virus reactivation from splenocytes arises from
latently infected B cells (21, 36), macrophages represent the major
latently infected cell type in PECs. Thus, to address whether the
observed defect in G50DblKo reactivation from splenocytes reflects a B cell-specific defect, we determined the frequency of PECs
reactivating virus. In contrast to the previous observation that the
G50pKo virus retained the ability to reactivate from PECs (16),
G50DblKo exhibited no detectable reactivation from PECs
(Fig. 10C and Table 1). As expected, both wild-type MHV68
and the G50DblKo.MR virus reactivated from PECs, at frequencies of 1 in 17,782 cells and 1 in 14,417 cells, respectively
(Fig. 10C and Table 1). These results indicate that despite the
ability to drive viral replication, the absence of both the proximal and distal gene 50 promoters results in a substantial impairment in the ability of MHV68 to reactivate from infected
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cells in vivo. Despite rescue of establishment of latency in
splenocytes following intraperitoneal inoculation, a ca. 6-fold
defect in the establishment of latency in PECs was observed (the
frequency of viral genome-positive PECs in wild-type-infected
animals was 1 in 401 cells, in G50DblKo.MR-infected animals it
was 1 in 562 cells, and in G50DblKo-infected animals it was ca. 1 in
2,137 cells) (Fig. 10D and Table 1). Despite the modest impairment of the G50DblKo mutant in the establishment of latency in
PECs, it is clear that this mutant is significantly impaired in reactivation from latency from both splenic B cells and peritoneal
macrophages.
The G50DblKo phenotype in vivo is partially rescued in mice
lacking the IFN-␣/␤ receptor. Since we have shown that the
G50DblKo mutant virus retains the ability to grow with normal
kinetics and to high titer in cells that lack a type I IFN response
(Fig. 4B and 5B), we assessed whether the absence of a type I IFN
response in vivo would rescue the G50DblKo replication and reactivation defects. Thus, we infected 129S2/SvPas.IFN-␣/␤R⫺/⫺
mice with 1,000 PFU of either the G50DblKo mutant or wild-type
MHV68 via intranasal inoculation. It has previously been shown
that MHV68 infection of mice lacking the IFN-␣/␤ receptor results in the majority of mice succumbing during the acute phase of
infection (26–28, 37). Surprisingly, while the G50DblKo mutant
replicated to high titers in the lungs of IFN-␣/␤R⫺/⫺ mice (Fig.
11C), all infected mice survived (Fig. 11A). However, as expected,
only 3 of 19 mice infected with 1,000 PFU wild-type MHV68 WT
virus survived past 2 weeks postinfection (Fig. 11A). Parallel analyses in C57BL/6 mice confirmed the severe replication defect observed with the G50DblKo mutant (virus replication in the lungs
was below the limit of detection in all infected mice). Notably,
acute replication of the G50DblKo mutant in the lungs of IFN-␣/
␤R⫺/⫺ mice was rescued to near-wild-type MHV68 levels (Fig.
11C). To further address the absence of lethality in IFN-␣/␤R⫺/⫺
mice with the G50DblKo mutant, we extended these studies using
higher inoculating doses. We did not observe any lethality, even
when mice were infected with a ca. 400-fold-higher dose of the
G50DblKo mutant (5 of 5 mice infected survived for greater than
4 weeks postinfection) (Fig. 11D). Thus, while acute virus replication of the G50DblKo mutant in the lungs following intranasal
inoculation was largely rescued by loss of a type I IFN response,
MHV68-associated lethality was not observed, indicating a requirement for the gene 50 proximal and/or distal promoter for
RTA expression in some anatomical site during the acute phase of
virus infection.
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FIG 11 Infection of 129S2/SvPas.IFN-␣/␤R⫺/⫺ mice with G50DblKo virus
does not result in lethality as seen with WT virus, despite the presence of high
viral titers in the lungs. (A) Kaplan-Meier curve depicting survival of 129S2/
SvPas.IFN-␣/␤R⫺/⫺ mice when challenged with 1,000 PFU i.n. of WT or
G50DblKo virus. (B) Lung titers at day 7 from C57BL/6 mice infected with
1,000 PFU i.n. of G50DblKo or G50DblKo.MR virus. (C) Lung titers at day 7
from 129S2/SvPas.IFN-␣/␤R⫺/⫺ mice infected with 1,000 PFU i.n. of
G50DblKo or G50DblKo.MR virus. (D) Kaplan-Meier curve depicting survival of 129S2/SvPas.IFN-␣/␤R⫺/⫺ mice when challenged with 440,000 PFU
i.n. of G50DblKo virus compared to survival of mice when challenged with
1,000 PFU G50DblKo.MR virus.

Having shown that the severe defect in acute replication of the
G50DblKo mutant observed in C57BL/6 mice was largely rescued
in mice lacking the ability to respond to type I IFNs, we assessed
establishment of latency and virus reactivation in IFN-␣/␤R⫺/⫺
mice. Spleens were harvested at day 28 from IFN-␣/␤R⫺/⫺ mice
intranasally infected with 1,000 PFU of either wild-type or
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G50DblKo virus. It is important to note that the latency and reactivation analyses for wild-type virus-infected IFN-␣/␤R⫺/⫺ mice
were carried out using the subset of infected animals that survived
acute virus replication (Fig. 10A). Like the rescue of acute virus
replication in the lungs, the frequency of viral genome-positive
splenocytes went from a ca. 8-fold defect in i.n. infected C57BL/6
mice (Fig. 10B) to an almost identical frequency of virus-infected
splenocytes in IFN-␣/␤R⫺/⫺ mice (1 in 131 cells for wild-type
MHV68 and 1 in 133 for the G50DblKo mutant) (Fig. 12A and
Table 1). More importantly, the defect in virus reactivation observed in C57BL/6 mice was completely rescued in IFN-␣/␤R⫺/⫺
mice (1 in 77,624 splenocytes in WT-infected mice compared to 1
in 52,420 splenocytes in G50DblKo virus-infected mice) (Fig. 12B
and Table 1). The latter result argues in favor of a model in which
the sole defect in G50DblKo virus reactivation from C57BL/6
splenocytes is the inability to overcome type I IFN suppression of
virus replication.
One possible explanation for the ability of the G50DblKo virus
to replicate in the absence of type I interferons would be an increased expression of E1-E2 transcripts. This would make the
G50DblKo virus not a true double promoter knockout virus, as
E1-E2 transcripts would be responsible for the ability of the virus
to replicate. However, this does not appear to be the case because
(i) as shown in Fig. 6, RTA expression from the G50DblKo in
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FIG 12 G50DblKo virus establishes latency and reactivates to similar levels as
WT virus when used to infect 129S2/SvPas.IFN-␣/␤R⫺/⫺ mice in vivo. Female
129S2/SvPas.IFN-␣/␤R⫺/⫺ mice were infected with 1,000 PFU of G50DblKo
virus, WT virus, or G50DblKo.MR virus by intranasal injection. Mice surviving at day 28 postinfection (n ⫽ 20 for G50DblKo; n ⫽ 3 for WT/
G50DblKo.MR) were harvested for splenocytes and assessed for establishment
of latency and reactivation from latency. (A) As for Fig. 10A, splenocytes were
serially diluted and used in a CPE assay to look for the frequency of viral
reactivating cells. (B) As for Fig. 10B, splenocytes were serially diluted and used
in a nested PCR assay to look for the frequency of viral genome-positive cells.

Alternative MHV68 Gene 50 Transcripts

normal fibroblasts is not impaired, and (ii) analysis of 5= RACE
products generated from Vero cells, as well as IFN-␣/␤R⫺/⫺
MEFs, using the G50DblKo virus failed to detect any proximal
promoter (E1-E2)- or distal promoter (E0-E1-E2)-initiated transcripts. However, to more directly assess potential residual proximal promoter activity in the absence of a type I IFN response, we
cloned both the proximal promoter and the proximal promoter
deletion mutant into the pGL4.10Luc reporter plasmid. These reporter constructs were transfected into Vero cells, in the presence
and absence of IFN-␣ treatment. Importantly, the proximal promoter does not appear to be sensitive to the presence of IFN-␣
(Fig. 13), which is consistent with the results shown in Fig. 5D
where pretreatment with IFN-␣ has no effect on WT MHV68
growth. Furthermore, the proximal promoter deletion mutant exhibited significant lower promoter activity, in both the presence
and absence of added IFN-␣. Thus, taken together, these results
argue against proximal promoter-driven RTA expression accounting for the rescue of G50DblKo virus replication in the absence of type I IFN.
DISCUSSION

Here we demonstrate that MHV68 gene 50 transcription is more
complex than previously reported (6, 12, 16). Based on the current
analyses, MHV68 RTA expression can be driven from four distinct
promoters, and these promoters drive expression of 5 different
spliced gene 50 transcripts. The identification of multiple promoters driving expression of a single gene is not a novel concept; there
are many human and viral genes whose expression has been
shown to be regulated by multiple promoters (38–42). For example, EBV has been shown to use differential splicing and from 2
distinct promoters in the generation of the transcripts encoding
the six EBNA gene products (43–47). The use of multiple promot-
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FIG 13 Promoter activity in the region immediately 5= to the MHV68 proximal promoter and proximal promoter deletion. Vero cells were transfected
with pGL4.10[luc] luciferase reporter constructs containing either 410 bp upstream of exon 1 or 340 bp upstream of exon 1 containing the 70-bp deletion as
shown in Fig. 3A. Vero cells were stimulated with IFN-␣ (10,000 IU/ml) at 24
h after transfection, and at 48 h after transfection luciferase assays were performed. Data are presented as the fold difference of firefly luciferase activity
versus the pGL4.10[luc] empty vector control. The data represent triplicates at
least three independent transfections.

ers is often the result of a complex life cycle and/or, particularly
in the case of viruses, the infection of multiple cell types. We have
shown that alternatively initiated gene 50 transcripts are conserved in MHV68-, KSHV-, and EBV-infected cells, having
previously reported the detection of both proximal and distal promoter-initiated gene 50 transcripts (16). In addition, it has been
previously shown by others that HVS RTA expression is driven
from distinctly initiated transcripts expressed at different times in
the viral replication cycle (48). Here we identify 2 additional gene
50 transcription initiation sites; gene 50 transcripts arising from
these promoters could be detected in MHV68 infection of a macrophage cell line (RAW 264.7), a nonhuman primate epithelial cell
line (Vero), and IFN-␣/␤R⫺/⫺ mouse embryonic fibroblasts, indicating that these promoters appear to be widely active during
virus replication and not restricted to a particular cell type. However, we have not carried out a detailed analysis of the abundance
of specific gene 50 transcript species as a function of cell type or
time postinfection, and it is certainly possible that their activities
in vivo are more restricted. Thus, the current analyses do not rule
out the possibility that the identified gene 50 promoters behave
differently depending on cell type infected or address the role that
each promoter plays in different cell types during the course of
infection.
The utility of MHV68 infection of mice is that it provides a
tractable small animal model to identify basic aspects of gammaherpesvirus pathogenesis that may be relevant to the human viruses EBV and KSV. Thus, we have begun to explore whether the
complex gene 50 transcription observed during MHV68 replication is conserved in the human viruses. Notably, our preliminary
characterization of gene 50 transcription during KSHV reactivation from latently infected B cells has identified multiple distinct
gene 50 transcription initiation sites, as well as alternative splicing
that is very similar to that observed in MHV68-infected cells (data
not shown). Further analyses are necessary to fully characterize
these novel gene 50 transcripts expressed during KSHV reactivation from B cells, as well as to characterize BRLF1 transcription
during EBV infection.
The data presented here are among a limited number of studies
(49) showing that type I interferons play an important role in
suppressing MHV68 replication in tissue culture. This is strikingly
different from the case for WT MHV68, where in vitro growth is
not affected by the presence of type I interferons. However, it is
important to emphasize that in vivo type I interferons play a critical role in controlling acute MHV68 replication, as mice lacking
the IFN-␣/␤ receptor are highly susceptible to lethal MHV68 infection (27, 28). In addition, it has previously been shown that
type I interferons play a role in controlling viral reactivation from
latency (27, 50).
The levels of RTA protein were greatly reduced in G50DblKoinfected cells in the presence of a type I IFN response (Fig. 9A and
B), and abrogating the ability to respond to type I IFNs by disrupting IFN-␣/␤R rescued wild-type levels of RTA expression from
the G50DblKo mutant virus (Fig. 9C). Since RTA is the first immediate early gene expressed during gammaherpesvirus infection,
it directly and indirectly begins the lytic replication cascade by
turning on a variety of downstream genes (51–57). Many of these
downstream genes are responsible for an anti-type I interferon
response, such as Orf45, M2, and Orf54 (58–63). Importantly, the
ability of MHV68 to overcome the type I IFN response appears to
be not only essential but also immediate. Growth curves where
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where substantially higher levels of virus replication are observed
in the lungs of type I interferon-unresponsive mice than in those
of wild-type mice following i.n. virus inoculation (e.g., see Fig. 11)
(28). Based on the observations with G50DblKo mutant replication in vitro, it is perhaps reasonable to speculate that during acute
virus replication there may be a role for type I IFN-sensitive gene
50 transcription. Future studies will address whether any of the
newly identified gene 50 transcripts play such a role during acute
virus replication in vivo.
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IFN-␣ was added prior to infection and during infection (Fig. 5D)
demonstrate that the virus is able to overcome a type I IFN-induced antiviral cell environment; wild-type MHV68, even at a low
MOI, is unaffected by IFN-␣ treatment. We hypothesize, then,
that this may involve three distinct mechanisms. First, the virion
contains a viral protein(s) able to suppress the type I IFN response.
MHV68 proteins associated with the virion have been identified,
and this includes the Orf45-encoded protein, which has already
been implicated in regulating the type I IFN response (64). Second, RTA may itself be involved in mediating an anti-type I IFN
response, but this would likely require that sufficient levels of RTA
be expressed in an appropriate time frame postinfection to be
effective. Third, RTA expression and function may be insensitive
to type I interferon effects and thus able to initiate downstream
gene signaling despite the presence of an antiviral cellular state.
Future studies will need to address these possibilities.
It is notable that replication of G50DblKo is partially rescued in
high-MOI infection. However, replication following high-MOI
infection is still severely impaired (as shown in Fig. 6, titers never
rise significantly above the input levels). Furthermore, this likely
reflects the difference between a single cycle of replication versus
the multiple rounds of replication required followed low-MOI
infection. Indeed, following high-MOI infection, initial RTA levels following infection with the G50DblKo virus are higher than
those in WT virus-infected fibroblasts, but these levels decrease
over time (Fig. 6B, hours 16, 20, and 24). This indicates that RTA
expression is dysregulated in G50DblKo infected cells and this
likely impacts the tightly regulated lytic cascade ultimately leading
to diminished virus production and the observed small plaque
phenotype (Fig. 6C).
Overall these studies further reveal the complex nature of gammaherpesviruses replication. The identification of 3 additional
Orf50 transcripts was surprising but likely illustrates how the virus
has evolved to carefully control expression of the essential lytic
switch gene. Though beyond the scope of this study, future work
will investigate the function of these alternative gene 50 promoters
and transcripts, as well as their presence/absence in other gammaherpesviruses. It is clear that in the absence of type I interferons,
the newly identified gene 50 transcripts are able to drive viral replication nearly as efficiently as wild-type MHV68. This suggests
that these promoters may play a cell type-specific and/or timedependent role in the viral life cycle. Indeed, independent studies
have recently revealed that the N4/N5 promoter is responsive to
interleukin-4 (IL-4) treatment in macrophages, which has been
shown to trigger MHV68 reactivation from latently infected macrophages (T. A. Reese et al., unpublished data). Another possibility is that upstream-initiated gene 50 transcription may, under
some conditions, serve to suppress RTA expression by interfering
with transcription from the more proximal gene 50 promoters.
Transcriptional interference has been shown before for some EBV
transcripts (44, 65–67). In addition, the role of the short ATGinitiated open reading frames in the 5= untranslated regions of
upstream-initiated gene 50 transcripts remains to be investigated.
In summary, the analysis of the G50DblKo mutant extends our
understanding of RTA expression and has revealed a hithertounappreciated complexity of gene 50 transcription. It is notable
that until the analysis of the G50DblKo mutant, little or no impact
of type I interferons on wild-type MHV68 replication was observed. This was in stark contrast to the analysis of MHV68 replication during the acute stages of infection in IFN-␣/␤R⫺/⫺ mice,

Alternative MHV68 Gene 50 Transcripts

17.

18.
19.

21.
22.

23.
24.

25.

26.

27.

28.
29.
30.
31.

32.
33.

34.

35.
36.

May 2014 Volume 88 Number 10

37. Paden CR, Forrest JC, Moorman NJ, Speck SH. 2010. Murine gammaherpesvirus 68 LANA is essential for virus reactivation from splenocytes
but not long-term carriage of viral genome. J. Virol. 84:7214 –7224. http:
//dx.doi.org/10.1128/JVI.00133-10.
38. Koenigsberger C, Chicca JJ, II, Amoureux MC, Edelman GM, Jones FS.
2000. Differential regulation by multiple promoters of the gene encoding
the neuron-restrictive silencer factor. Proc. Natl. Acad. Sci. U. S. A. 97:
2291–2296. http://dx.doi.org/10.1073/pnas.050578797.
39. Delaloy C, Lu J, Houot AM, Disse-Nicodeme S, Gasc JM, Corvol P,
Jeunemaitre X. 2003. Multiple promoters in the WNK1 gene: one controls
expression of a kidney-specific kinase-defective isoform. Mol. Cell. Biol. 23:
9208 –9221. http://dx.doi.org/10.1128/MCB.23.24.9208-9221.2003.
40. Ozbun MA, Meyers C. 1998. Temporal usage of multiple promoters
during the life cycle of human papillomavirus type 31b. J. Virol. 72:2715–
2722.
41. Mitsui S, Nakamura T, Okui A, Kominami K, Uemura H, Yamaguchi
N. 2006. Multiple promoters regulate tissue-specific alternative splicing of
the human kallikrein gene, KLK11/hippostasin. FEBS J. 273:3678 –3686.
http://dx.doi.org/10.1111/j.1742-4658.2006.05372.x.
42. Kim JD, Kim CH, Kwon BS. 2011. Regulation of mouse 4-1BB expression: multiple promoter usages and a splice variant. Mol. Cells 31:141–
149. http://dx.doi.org/10.1007/s10059-011-0018-6.
43. Bodescot M, Perricaudet M, Farrell PJ. 1987. A promoter for the highly
spliced EBNA family of RNAs of Epstein-Barr virus. J. Virol. 61:3424 –
3430.
44. Woisetschlaeger M, Strominger JL, Speck SH. 1989. Mutually exclusive
use of viral promoters in Epstein-Barr virus latently infected lymphocytes.
Proc. Natl. Acad. Sci. U. S. A. 86:6498 – 6502. http://dx.doi.org/10.1073
/pnas.86.17.6498.
45. Rogers RP, Woisetschlaeger M, Speck SH. 1990. Alternative splicing
dictates translational start in Epstein-Barr virus transcripts. The EMBO
journal. 9:2273–2277.
46. Speck SH, Strominger JL. 1985. Analysis of the transcript encoding the
latent Epstein-Barr virus nuclear antigen I: a potentially polycistronic
message generated by long-range splicing of several exons. Proc. Natl.
Acad. Sci. U. S. A. 82:8305– 8309. http://dx.doi.org/10.1073/pnas.82.24
.8305.
47. Speck SH, Pfitzner A, Strominger JL. 1986. An Epstein-Barr virus transcript from a latently infected, growth-transformed B-cell line encodes a
highly repetitive polypeptide. Proc. Natl. Acad. Sci. U. S. A. 83:9298 –9302.
http://dx.doi.org/10.1073/pnas.83.24.9298.
48. Whitehouse A, Carr IM, Griffiths JC, Meredith DM. 1997. The herpesvirus saimiri ORF50 gene, encoding a transcriptional activator homologous to the Epstein-Barr virus R protein, is transcribed from two distinct
promoters of different temporal phases. J. Virol. 71:2550 –2554.
49. Wood BM, Mboko WP, Mounce BC, Tarakanova VL. 2013. Mouse
gammaherpesvirus-68 infection acts as a rheostat to set the level of type I
interferon signaling in primary macrophages. Virology 443:123–133. http:
//dx.doi.org/10.1016/j.virol.2013.04.036.
50. Mandal P, Krueger BE, Oldenburg D, Andry KA, Beard RS, White DW,
Barton ES. 2011. A gammaherpesvirus cooperates with interferon-alpha/
beta-induced IRF2 to halt viral replication, control reactivation, and minimize host lethality. PLoS Pathog. 7:e1002371. http://dx.doi.org/10.1371
/journal.ppat.1002371.
51. Chen J, Ye F, Xie J, Kuhne K, Gao SJ. 2009. Genome-wide identification
of binding sites for Kaposi’s sarcoma-associated herpesvirus lytic switch
protein, RTA. Virology. 386:290 –302. http://dx.doi.org/10.1016/j.virol
.2009.01.031.
52. Liu Y, Cao Y, Liang D, Gao Y, Xia T, Robertson ES, Lan K. 2008.
Kaposi’s sarcoma-associated herpesvirus RTA activates the processivity
factor ORF59 through interaction with RBP-Jkappa and a cis-acting RTA
responsive element. Virology 380:264 –275. http://dx.doi.org/10.1016/j
.virol.2008.08.011.
53. Deng H, Liang Y, Sun R. 2007. Regulation of KSHV lytic gene expression.
Curr. Top. Microbiol. Immunol. 312:157–183. http://dx.doi.org/10.1007
/978-3-540-34344-8_6.
54. Matsumura S, Fujita Y, Gomez E, Tanese N, Wilson AC. 2005. Activation of the Kaposi’s sarcoma-associated herpesvirus major latency locus
by the lytic switch protein RTA (ORF50). J. Virol. 79:8493– 8505. http://dx
.doi.org/10.1128/JVI.79.13.8493-8505.2005.
55. Song MJ, Deng H, Sun R. 2003. Comparative study of regulation of
RTA-responsive genes in Kaposi’s sarcoma-associated herpesvirus/

jvi.asm.org 5489

Downloaded from http://jvi.asm.org/ on May 13, 2014 by Washington University in St. Louis

20.

man gammaherpesvirus reactivation from latency. J. Virol. 83:314 –328.
http://dx.doi.org/10.1128/JVI.01444-08.
Paden CR, Forrest JC, Tibbetts SA, Speck SH. 2012. Unbiased mutagenesis of MHV68 LANA reveals a DNA-binding domain required for LANA
function in vitro and in vivo. PLoS Pathog. 8:e1002906. http://dx.doi.org
/10.1371/journal.ppat.1002906.
Warming S. 2005. Simple and highly efficient BAC recombineering using
galK selection. Nucleic Acids Res. 33:e36 – e36. http://dx.doi.org/10.1093
/nar/gni035.
Collins CM, Boss JM, Speck SH. 2009. Identification of infected B-cell
populations by using a recombinant murine gammaherpesvirus 68 expressing a fluorescent protein. J. Virol. 83:6484 – 6493. http://dx.doi.org
/10.1128/JVI.00297-09.
Weck KE, Barkon ML, Yoo LI, Speck SH, Virgin HI. 1996. Mature B
cells are required for acute splenic infection, but not for establishment of
latency, by murine gammaherpesvirus 68. J. Virol. 70:6775– 6780.
Weck KE, Kim SS, Virgin HI, Speck SH. 1999. B cells regulate murine
gammaherpesvirus 68 latency. J. Virol. 73:4651– 4661.
Dong X, He Z, Durakoglugil D, Arneson L, Shen Y, Feng P. 2012.
Murine gammaherpesvirus 68 evades host cytokine production via replication transactivator-induced RelA degradation. J. Virol. 86:1930 –1941.
http://dx.doi.org/10.1128/JVI.06127-11.
Pavlova IV, Virgin HW, Speck SH. 2003. Disruption of gammaherpesvirus
68 gene 50 demonstrates that Rta is essential for virus replication. J. Virol.
77:5731–5739. http://dx.doi.org/10.1128/JVI.77.10.5731-5739.2003.
Moorman NJ, Willer DO, Speck SH. 2003. The gammaherpesvirus 68
latency-associated nuclear antigen homolog is critical for the establishment of splenic latency. J. Virol. 77:10295–10303. http://dx.doi.org/10
.1128/JVI.77.19.10295-10303.2003.
Adler H, Messerle M, Koszinowski UH. 2001. Virus reconstituted from
infectious bacterial artificial chromosome (BAC)-cloned murine gammaherpesvirus 68 acquires wild-type properties in vivo only after excision of
BAC vector sequences. J. Virol. 75:5692–5696. http://dx.doi.org/10.1128
/JVI.75.12.5692-5696.2001.
Arico E, Robertson KA, Belardelli F, Ferrantini M, Nash AA. 2004.
Vaccination with inactivated murine gammaherpesvirus 68 strongly limits viral replication and latency and protects type I IFN receptor knockout
mice from a lethal infection. Vaccine 22:1433–1440. http://dx.doi.org/10
.1016/j.vaccine.2003.10.015.
Barton ES, Lutzke ML, Rochford R, Virgin HW, IV. 2005. Alpha/beta
interferons regulate murine gammaherpesvirus latent gene expression
and reactivation from latency. J. Virol. 79:14149 –14160. http://dx.doi.org
/10.1128/JVI.79.22.14149-14160.2005.
Dutia BM, Allen DJ, Dyson H, Nash AA. 1999. Type I interferons and
IRF-1 play a critical role in the control of a gammaherpesvirus infection.
Virology 261:173–179. http://dx.doi.org/10.1006/viro.1999.9834.
El-Guindy A, Ghiassi-Nejad M, Golden S, Delecluse HJ, Miller G. 2013.
Essential role of Rta in lytic DNA replication of Epstein-Barr virus. J. Virol.
87:208 –223. http://dx.doi.org/10.1128/JVI.01995-12.
Guito J, Lukac DM. 2012. KSHV Rta promoter specification and viral reactivation. Front. Microbiol. 3:30. http://dx.doi.org/10.3389/fmicb.2012.00030.
Wang Y, Tang Q, Maul GG, Yuan Y. 2006. Kaposi’s sarcoma-associated
herpesvirus ori-Lyt-dependent DNA replication: dual role of replication
and transcription activator. J. Virol. 80:12171–12186. http://dx.doi.org/10
.1128/JVI.00990-06.
Wu TT, Tong L, Rickabaugh T, Speck S, Sun R. 2001. Function of Rta
is essential for lytic replication of murine gammaherpesvirus 68. J. Virol.
75:9262–9273. http://dx.doi.org/10.1128/JVI.75.19.9262-9273.2001.
Goodwin MM, Canny S, Steed A, Virgin HW. 2010. Murine gammaherpesvirus 68 has evolved gamma interferon and stat1-repressible promoters for the lytic switch gene 50. J. Virol. 84:3711–3717. http://dx.doi
.org/10.1128/JVI.02099-09.
Krug LT, Collins CM, Gargano LM, Speck SH. 2009. NF-kappaB p50
plays distinct roles in the establishment and control of murine gammaherpesvirus 68 latency. J. Virol. 83:4732– 4748. http://dx.doi.org/10.1128
/JVI.00111-09.
Coleman CB, Nealy MS, Tibbetts SA. 2010. Immature and transitional B
cells are latency reservoirs for a gammaherpesvirus. J. Virol. 84:13045–
13052. http://dx.doi.org/10.1128/JVI.01455-10.
Liang X, Collins CM, Mendel JB, Iwakoshi NN, Speck SH. 2009.
Gammaherpesvirus-driven plasma cell differentiation regulates virus reactivation from latently infected B lymphocytes. PLoS Pathog.
5:e1000677. http://dx.doi.org/10.1371/journal.ppat.1000677.

Wakeman et al.

56.
57.

58.

60.

61.

5490

jvi.asm.org

62. Zhu FX, King SM, Smith EJ, Levy DE, Yuan Y. 2002. A Kaposi’s
sarcoma-associated herpesviral protein inhibits virus-mediated induction
of type I interferon by blocking IRF-7 phosphorylation and nuclear accumulation. Proc. Natl. Acad. Sci. U. S. A. 99:5573–5578. http://dx.doi.org
/10.1073/pnas.082420599.
63. Leang RS, Wu TT, Hwang S, Liang LT, Tong L, Truong JT, Sun R. 2011.
The anti-interferon activity of conserved viral dUTPase ORF54 is essential
for an effective MHV-68 infection. PLoS Pathog. 7:e1002292. http://dx
.doi.org/10.1371/journal.ppat.1002292.
64. Bortz E, Whitelegge JP, Jia Q, Zhou ZH, Stewart JP, Wu TT, Sun R.
2003. Identification of proteins associated with murine gammaherpesvirus 68 virions. J. Virol. 77:13425–13432. http://dx.doi.org/10.1128/JVI.77
.24.13425-13432.2003.
65. Paulson EJ, Fingeroth JD, Yates JL, Speck SH. 2002. Methylation of the
EBV genome and establishment of restricted latency in low-passage EBVinfected 293 epithelial cells. Virology 299:109 –121. http://dx.doi.org/10
.1006/viro.2002.1457.
66. Schaefer BC, Strominger JL, Speck SH. 1997. Host-cell-determined
methylation of specific Epstein-Barr virus promoters regulates the choice
between distinct viral latency programs. Mol. Cell. Biol. 17:364 –377.
67. Woisetschlaeger M, Yandava CN, Furmanski LA, Strominger JL, Speck
SH. 1990. Promoter switching in Epstein-Barr virus during the initial
stages of infection of B lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 87:
1725–1729. http://dx.doi.org/10.1073/pnas.87.5.1725.

Journal of Virology

Downloaded from http://jvi.asm.org/ on May 13, 2014 by Washington University in St. Louis

59.

human herpesvirus 8. J. Virol. 77:9451–9462. http://dx.doi.org/10.1128
/JVI.77.17.9451-9462.2003.
Ragoczy T, Miller G. 1999. Role of the Epstein-Barr virus RTA protein in
activation of distinct classes of viral lytic cycle genes. J. Virol. 73:9858 –
9866.
Chang Y, Lee HH, Chang SS, Hsu TY, Wang PW, Chang YS, Takada K,
Tsai CH. 2004. Induction of Epstein-Barr virus latent membrane protein
1 by a lytic transactivator Rta. J. Virol. 78:13028 –13036. http://dx.doi.org
/10.1128/JVI.78.23.13028-13036.2004.
Zhu FX, Sathish N, Yuan Y. 2010. Antagonism of host antiviral responses
by Kaposi’s sarcoma-associated herpesvirus tegument protein ORF45.
PLoS One 5:e10573. http://dx.doi.org/10.1371/journal.pone.0010573.
Liang X, Shin YC, Means RE, Jung JU. 2004. Inhibition of interferonmediated antiviral activity by murine gammaherpesvirus 68 latencyassociated M2 protein. J. Virol. 78:12416 –12427. http://dx.doi.org/10
.1128/JVI.78.22.12416-12427.2004.
Liang Q, Fu B, Wu F, Li X, Yuan Y, Zhu F. 2012. ORF45 of Kaposi’s
sarcoma-associated herpesvirus inhibits phosphorylation of interferon
regulatory factor 7 by IKKepsilon and TBK1 as an alternative substrate. J.
Virol. 86:10162–10172. http://dx.doi.org/10.1128/JVI.05224-11.
Sathish N, Zhu FX, Golub EE, Liang Q, Yuan Y. 2011. Mechanisms of
autoinhibition of IRF-7 and a probable model for inactivation of IRF-7 by
Kaposi’s sarcoma-associated herpesvirus protein ORF45. J. Biol. Chem.
286:746 –756. http://dx.doi.org/10.1074/jbc.M110.150920.

